Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherap. LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 9.625p 9.50p 9.75p 9.625p 9.625p 9.625p 108,691 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 11.43

SkinBioTherapeutics PLC SkinBioTherapeutics to Present at Investor Evening

19/06/2017 9:00am

RNS Non-Regulatory


TIDMSBTX

SkinBioTherapeutics PLC

19 June 2017

SkinBioTherapeutics plc

SkinBioTherapeutics to Present at Investor Evening

Manchester, UK - 19 June 2017 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, is pleased to announce that Dr Catherine O'Neill (CEO) will be presenting at an investor evening held in London, EC4 hosted by Turner Pope Investments (TPI) Ltd.

The event will be held on Thursday 29(th) June and will commence at 5pm.

To register your interest, please email info@turnerpope.com or call 0203 621 4121.

Ends

For more information, please contact:

 
 SkinBioTherapeutics plc     Tel: +44 (0) 161 468 
  Dr. Catherine O'Neill,      2760 
  CEO 
  Douglas Quinn, CFO 
 Turner Pope Investments     Tel: +44 (0) 20 3621 
  Ben Turner / James Pope     4120 
 Instinctif Partners         Tel: +44 (0) 20 7457 
  Melanie Toyne-Sewell /      2020 
  Alex Shaw / Deborah Bell    SkinBio@instinctif.com 
 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas.

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix(R). The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising GBP4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAXKNFSEXEEF

(END) Dow Jones Newswires

June 19, 2017 04:00 ET (08:00 GMT)

1 Year Skinbiotherap. Chart

1 Year Skinbiotherap. Chart

1 Month Skinbiotherap. Chart

1 Month Skinbiotherap. Chart
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V:gb D:20170628 12:33:02